Literature DB >> 10993862

Functional protection by acute phase proteins alpha(1)-acid glycoprotein and alpha(1)-antitrypsin against ischemia/reperfusion injury by preventing apoptosis and inflammation.

M A Daemen1, V H Heemskerk, C van't Veer, G Denecker, T G Wolfs, P Vandenabeele, W A Buurman.   

Abstract

BACKGROUND: Ischemia followed by reperfusion (I/R) causes apoptosis, inflammation, and tissue damage leading to organ malfunction. Ischemic preconditioning can protect against such injury. This study investigates the contribution of the acute phase proteins alpha(1)-acid glycoprotein (AGP) and alpha(1)-antitrypsin (AAT) to the protective effect of ischemic preconditioning in the kidney. METHODS AND
RESULTS: Exogenous AGP and AAT inhibited apoptosis and inflammation after 45 minutes of renal I/R in a murine model. AGP and AAT administered at reperfusion prevented apoptosis at 2 hours and 24 hours, as evaluated by the presence of internucleosomal DNA cleavage, terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling, and the determination of renal caspase-1- and caspase-3-like activity. AGP and AAT exerted anti-inflammatory effects, as reflected by reduced renal tumor necrosis factor-alpha expression and neutrophil influx after 24 hours. In general, these agents improved renal function. Similar effects were observed when AGP and AAT were administered 2 hours after reperfusion but to a lesser extent and without functional improvement. Moreover, I/R elicited an acute phase response, as reflected by elevated serum AGP and serum amyloid P (SAP) levels after 24 hours, and increased hepatic acute phase protein mRNA levels after 18 hours of renal reperfusion.
CONCLUSIONS: We propose that the antiapoptotic and anti-inflammatory effects of AGP and AAT contribute to the delayed type of protection associated with ischemic preconditioning and other insults. This mechanism is potentially involved in the course of many clinical conditions associated with I/R injury. Moreover, exogenous administration of these proteins may provide new therapeutic means of treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10993862     DOI: 10.1161/01.cir.102.12.1420

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  49 in total

Review 1.  Mechanistic evidence in support of alpha1-antitrypsin as a therapeutic approach for type 1 diabetes.

Authors:  Gabriella Fleixo-Lima; Hilla Ventura; Michal Medini; Liliana Bar; Pnina Strauss; Eli C Lewis
Journal:  J Diabetes Sci Technol       Date:  2014-08-25

Review 2.  Lung disease associated with alpha1-antitrypsin deficiency.

Authors:  Rubin M Tuder; Sabina M Janciauskiene; Irina Petrache
Journal:  Proc Am Thorac Soc       Date:  2010-11

3.  Acute-phase protein α1-antitrypsin inhibits neutrophil calpain I and induces random migration.

Authors:  Mariam Al-Omari; Elena Korenbaum; Matthias Ballmaier; Ulrich Lehmann; Danny Jonigk; Dietmar J Manstein; Tobias Welte; Ravi Mahadeva; Sabina Janciauskiene
Journal:  Mol Med       Date:  2011-04-11       Impact factor: 6.354

Review 4.  Immune-modulating effects of alpha-1 antitrypsin.

Authors:  Mario R Ehlers
Journal:  Biol Chem       Date:  2014-10       Impact factor: 3.915

5.  Discovery of SERPINA3 as a candidate urinary biomarker of lupus nephritis activity.

Authors:  Jessica L Turnier; Hermine I Brunner; Michael Bennett; Ashwaq Aleed; Gaurav Gulati; Wendy D Haffey; Sherry Thornton; Michael Wagner; Prasad Devarajan; David Witte; Kenneth D Greis; Bruce Aronow
Journal:  Rheumatology (Oxford)       Date:  2019-02-01       Impact factor: 7.580

6.  Expression and secretion of alpha1-proteinase inhibitor are regulated by proinflammatory cytokines in human pancreatic islet cells.

Authors:  Domenico Bosco; Paolo Meda; Philippe Morel; David Matthey-Doret; Dorothée Caille; Christian Toso; Leo H Bühler; Thierry Berney
Journal:  Diabetologia       Date:  2005-07-07       Impact factor: 10.122

7.  Alpha 1-antitrypsin therapy mitigated ischemic stroke damage in rats.

Authors:  Huong L Moldthan; Aaron C Hirko; Jeffrey S Thinschmidt; Maria B Grant; Zhimin Li; Joanna Peris; Yuanqing Lu; Ahmed S Elshikha; Michael A King; Jeffrey A Hughes; Sihong Song
Journal:  J Stroke Cerebrovasc Dis       Date:  2014-02-28       Impact factor: 2.136

8.  Overexpression of alpha(1)-acid glycoprotein in transgenic mice leads to sensitisation to acute colitis.

Authors:  T Hochepied; A Wullaert; F G Berger; H Baumann; P Brouckaert; L Steidler; C Libert
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

9.  α-Linoleic acid enhances the capacity of α-1 antitrypsin to inhibit lipopolysaccharide induced IL-1β in human blood neutrophils.

Authors:  Nupur Aggarwal; Elena Korenbaum; Ravi Mahadeva; Stephan Immenschuh; Veronika Grau; Charles A Dinarello; Tobias Welte; Sabina Janciauskiene
Journal:  Mol Med       Date:  2016-10-04       Impact factor: 6.354

10.  Oxidized {alpha}1-antitrypsin stimulates the release of monocyte chemotactic protein-1 from lung epithelial cells: potential role in emphysema.

Authors:  Zhenjun Li; Sam Alam; Jicun Wang; Caroline S Sandstrom; Sabina Janciauskiene; Ravi Mahadeva
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-06-12       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.